Biocon subsidiary completes acquisition of Viatris for USD 3 billion
Nov 29, 2022
According to a statement by the pharma company, Biocon Biologics and Viatris have obtained all applicable approvals from key global regulators including the US Federal Trade Commission, the Competition Commission of India and the Reserve Bank of India, and its investors, respectively.